Prediction of colorectal cancer diagnosis based on circulating plasma proteins

Non‐invasive detection of colorectal cancer with blood‐based markers is a critical clinical need. Here we describe a phased mass spectrometry‐based approach for the discovery, screening, and validation of circulating protein biomarkers with diagnostic value. Initially, we profiled human primary tumor tissue epithelia and characterized about 300 secreted and cell surface candidate glycoproteins. These candidates were then screened in patient systemic circulation to identify detectable candidates in blood plasma. An 88‐plex targeting method was established to systematically monitor these proteins in two large and independent cohorts of plasma samples, which generated quantitative clinical datasets at an unprecedented scale. The data were deployed to develop and evaluate a five‐protein biomarker signature for colorectal cancer detection.

[1]  A. Stensballe,et al.  Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies. , 2014, World journal of gastroenterology.

[2]  H. Brenner,et al.  Comparative Evaluation of Immunochemical Fecal Occult Blood Tests for Colorectal Adenoma Detection , 2009, Annals of Internal Medicine.

[3]  A. Agresti,et al.  Categorical Data Analysis , 1991, International Encyclopedia of Statistical Science.

[4]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[5]  J. Roth.  Protein N-glycosylation along the secretory pathway: relationship to organelle topography and function, protein quality control, and cell interactions. , 2002, Chemical reviews.

[6]  R. Aebersold,et al.  Non-invasive prognostic protein biomarker signatures associated with colorectal cancer , 2015, EMBO molecular medicine.

[7]  Alexey I Nesvizhskii,et al.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. , 2002, Analytical chemistry.

[8]  R. Booth.  Minimally invasive biomarkers for detection and staging of colorectal cancer. , 2007, Cancer letters.

[9]  N. Anderson,et al.  A List of Candidate Cancer Biomarkers for Targeted Proteomics , 2006, Biomarker insights.

[10]  H. Brenner,et al.  Comparison and combination of blood-based inflammatory markers with faecal occult blood tests for non-invasive colorectal cancer screening , 2012, British Journal of Cancer.

[11]  John Greenwood,et al.  LRG1 promotes angiogenesis by modulating endothelial TGFß signalling , 2013, Nature.

[12]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[13]  G. Li,et al.  Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. , 1999, Cancer research.

[14]  Ruedi Aebersold,et al.  Targeted proteomic strategy for clinical biomarker discovery , 2009, Molecular oncology.

[15]  Brendan MacLean,et al.  MSstats: an R package for statistical analysis of quantitative mass spectrometry-based proteomic experiments , 2014, Bioinform..

[16]  L. Uhlin‐Hansen,et al.  Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets , 2013, Tumor Biology.

[17]  O. Linton.  Local Regression Models , 2010 .

[18]  S. Hanash,et al.  Increased Plasma Levels of the APC-Interacting Protein MAPRE1, LRG1, and IGFBP2 Preceding a Diagnosis of Colorectal Cancer in Women , 2012, Cancer Prevention Research.

[19]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[20]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[21]  N Leigh Anderson,et al.  High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. , 2008, Clinical chemistry.

[22]  Ruedi Aebersold,et al.  Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry , 2003, Nature Biotechnology.

[23]  B. Gray,et al.  Acute‐phase reactant proteins and carcinoembryonic antigen in cancer of the colon and rectum , 2006, Cancer.

[24]  L. Sobin,et al.  TNM: evolution and relation to other prognostic factors. , 2003, Seminars in surgical oncology.

[25]  F. Balaguer,et al.  Evaluation of Alpha 1-Antitrypsin and the Levels of mRNA Expression of Matrix Metalloproteinase 7, Urokinase Type Plasminogen Activator Receptor and COX-2 for the Diagnosis of Colorectal Cancer , 2013, PloS one.

[26]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[27]  A. Agresti.  Analysis of Ordinal Categorical Data: Agresti/Analysis , 2010 .

[28]  J. Greenwood,et al.  LRG1 promotes angiogenesis by modulating endothelial TGF-beta signalling (vol 499, pg 306, 2013) , 2013 .

[29]  Damon H. May,et al.  Investigating neoplastic progression of ulcerative colitis with label-free comparative proteomics. , 2011, Journal of proteome research.

[30]  Brendan MacLean,et al.  Bioinformatics Applications Note Gene Expression Skyline: an Open Source Document Editor for Creating and Analyzing Targeted Proteomics Experiments , 2022 .

[31]  H. Brenner,et al.  Case-Control Study Supports Extension of Surveillance Interval After Colonoscopic Polypectomy to at Least 5 Yr , 2007, The American Journal of Gastroenterology.

[32]  G. Can,et al.  Serum Lipid Hydroperoxide Levels and Paraoxonase Activity in Patients With Lung, Breast, and Colorectal Cancer , 2012, Journal of clinical laboratory analysis.

[33]  Andreas Quandt,et al.  An automated pipeline for high-throughput label-free quantitative proteomics. , 2013, Journal of proteome research.

[34]  Terry Speed,et al.  Normalization of cDNA microarray data. , 2003, Methods.

[35]  Daniel F Hayes,et al.  ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  E. Kuipers,et al.  Attendance and Yield Over Three Rounds of Population-Based Fecal Immunochemical Test Screening , 2014, The American Journal of Gastroenterology.

[37]  H. Brenner,et al.  Inter‐test agreement and quantitative cross‐validation of immunochromatographical fecal occult blood tests , 2010, International journal of cancer.

[38]  H. Nielsen,et al.  Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  R. Aebersold,et al.  A statistical model for identifying proteins by tandem mass spectrometry. , 2003, Analytical chemistry.

[40]  Knut Reinert,et al.  OpenMS – An open-source software framework for mass spectrometry , 2008, BMC Bioinformatics.

[41]  Trevor Hastie,et al.  Statistical Models in S , 1991 .

[42]  Susan E. Abbatiello,et al.  Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry-based Assay Development Using a Fit-for-Purpose Approach* , 2014, Molecular & Cellular Proteomics.

[43]  Gilbert S Omenn,et al.  Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project reference specimens: Systematic variation between sample types and calibration of mass spectrometry data , 2005, Proteomics.

[44]  J Chang-Claude,et al.  Does a negative screening colonoscopy ever need to be repeated? , 2005, Gut.

[45]  B. Larsen.  [Colorectal cancer screening]. , 2010, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[46]  R. Aebersold,et al.  Mass Spectrometric Detection of Tissue Proteins in Plasma*S , 2007, Molecular & Cellular Proteomics.

[47]  Luis Mendoza,et al.  PASSEL: The PeptideAtlas SRMexperiment library , 2012, Proteomics.

[48]  P. Heinrich,et al.  Hepatic acute phase proteins--regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling. , 2012, European journal of cell biology.

[49]  Bernd Wollscheid,et al.  CD proteome and beyond - technologies for targeting the immune cell surfaceome. , 2012, Frontiers in bioscience.

[50]  E. Eren,et al.  Diagnostic value of thiols, paraoxonase 1, arylesterase and oxidative balance in colorectal cancer in human. , 2013, Neoplasma.